Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European Commission

Access, MyelomaLeave a comment

The European Commission has approved two of Celgene’s IMiD ® -based combination regimens: Lenalidomide (Revlimid®) in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant Pomalidomide (Imnovid®) in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at least one prior treatment regimen including lenalidomide.

Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on access

Access, MPELeave a comment

Myeloma Patients Europe (MPE) has launched a Central and Eastern Europe (CEE) Workgroup on Access during our recent Annual General Meeting (AGM) in Munich, Germany. The Workgroup is chaired by MPE board members, Kristina Modic, also CEO of our Slovenian member Slovensko Združenje Bolnikov Z Limfomom In Levkemijo L&L, and Biba Dodeva, President of our Macedonian member BORKA. It was launched in response to an identified need for coordinated action at a European level on…

ESMO drives EU-level action to tackle shortages of essential medicines

AccessLeave a comment

Shortages of essential cancer medicines have a direct impact on patient care across Europe. To ensure that this issue remains a top priority on the EU policy agenda, the European Society for Medical Oncology (ESMO) collaborated with the European Parliament to organise a cross-partisan event entitled “Shortages of Inexpensive, Essential Medicines: Calling for Tangible Political Commitments in the EU”, according to a press release sent by ESMO today.

Huge variations between countries in time for reimbursement decisions on new cancer drugs

AccessLeave a comment

European Society for Medical Oncology (ESMO), Munich (Germany) – Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average decision time is longer than one year in some countries, according to a study presented at ESMO 2018 Congress.

Daratumumab receive European license for use in newly diagnosed myeloma

Access, MyelomaLeave a comment

Daratumumab (Darzalex®), an immunotherapy drug for the treatment of myeloma, has been granted marketing authorisation (e.g. a licence) by the European Commission. It is specifically licensed for use in combination with bortezomib (Velcade®), melphalan and prednisolone (D-VMP) in newly diagnosed myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation.